KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) EBT Margin (2016 - 2025)

Biogen (BIIB) has 17 years of EBT Margin data on record, last reported at 2.46% in Q4 2025.

  • For Q4 2025, EBT Margin fell 1433.0% year-over-year to 2.46%; the TTM value through Dec 2025 reached 15.74%, down 396.0%, while the annual FY2025 figure was 15.74%, 396.0% down from the prior year.
  • EBT Margin reached 2.46% in Q4 2025 per BIIB's latest filing, down from 21.99% in the prior quarter.
  • Across five years, EBT Margin topped out at 54.66% in Q3 2022 and bottomed at 5.58% in Q3 2023.
  • Average EBT Margin over 5 years is 19.79%, with a median of 18.04% recorded in 2023.
  • Peak YoY movement for EBT Margin: skyrocketed 4418bps in 2022, then plummeted -6024bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 14.81% in 2021, then skyrocketed by 60bps to 23.73% in 2022, then crashed by -124bps to 5.58% in 2023, then soared by 313bps to 11.88% in 2024, then crashed by -121bps to 2.46% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 2.46% in Q4 2025, 21.99% in Q3 2025, and 28.12% in Q2 2025.